Loading the content... Loading depends on your connection speed!

Shopping Cart - $0.00

Biologics Global Market Report 2018

Biologics Global Market Report 2018

From $4,000.00

Including: Healthcare Services, Pharmaceutical Drugs, Medical Equipment, And Biologics
Covering: Amgen, AbbVie, Johnson & Johnson, Bristol-Meyers Squib, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co., GlaxoSmithKline, Sanofi


Clear selection
SKU: 2793. Category: .
Description

Biologics Global Market Report 2018 from The Business Research Company provides the strategists, marketers and senior management with the critical information they need to assess the global biologics market.

Reasons to Purchase

Reasons to Purchase
• Outperform competitors using accurate up to date demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
• Create regional and country strategies on the basis of local data and analysis.
• Stay abreast of the latest customer and market research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future developments.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Gain a global perspective on the development of the market.

Description:
Where is the largest and fastest growing market for the biologics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biologics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider healthcare market, and compares it with other markets.
• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
• Market segmentations break down market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
• Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
• The biologics market section of the report gives context. It compares the biologics market with other segments of the healthcare market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Biologics Market Indicators Comparison.

 

Scope

Markets Covered: Healthcare Services, Pharmaceutical Drugs, Medical Equipment, And Biologics

Companies Mentioned: Amgen, AbbVie, Johnson & Johnson, Bristol-Meyers Squib, Pfizer, Eli Lilly and Company, F. Hoffmann-La Roche, Merck & Co., GlaxoSmithKline, Sanofi

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Biologics Market Indicators Comparison.

Data segmentations: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table Of Contents
1.Biologics Market Characteristics
1.1. Market Overview
1.2. Segmentations
1.2.1. Monoclonal Antibodies
1.2.2. Therapeutic proteins
1.2.3. Vaccines
1.3. Market Value Chain

2. Biologics Market Trends and Strategies

3. Biologics Market Size & Growth
3.1. Historic Market Growth
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Market Forecast Growth
3.2.1. Drivers Of The Market
3.2.2. Restraints On The Market
4. PESTLE Analysis
4.1. Political
4.2. Economic
4.3. Social
4.4. Technological
4.5. Legal
4.6. Environmental

5. Biologics Market Segmentation
5.1. Global Biologics Market, 2017, Split By Segments: By Product Type
5.2. Global Biologics Market, Historic and Forecast, Split By Segments, 2013-2021

6. Global Biologics Market Compared With Similar Markets, 2017
6.1. Global Biologics Market Compared With Similar Markets, 2013 - 2021, Historic and Forecast
6.2. Global Biologics Market Segment Details

7. Biologics Market Geography Regional and Country Analysis
7.1. Global Biologics Market, 2017, By Region
7.2. Global Biologics Market, Historic And Forecast Growth Rate, Split By Region, 2013-2021
7.3. Global Biologics Market, Split By Country, 2017
7.4. Global Biologics Market, Historic And Forecast Growth Rate, Split By Country, 2013-2021
8. Global Biologics Market Comparison with Macro Economic Factors
8.1. Biologics Market Size, Percentage Of GDP, Global
8.2. Per Capita Average Biologics Expenditure, Global
9. Global Biologics Market Comparison With Industry Metrics
9.1. Global Number Of Biotech Enterprises, By Country
9.2. Global Average Spending On R & D / Product Development, 2016, By Country
9.3. Global Biologics Market Revenue Versus Average Spending On R & D / Product Development, 2016, By Country
9.4. Global Biologic Drugs under Development
9.5. Global New Biologics Approved, By Country
9.6. Global Number Of General Practitioners 2016, By Country
10. Asia-Pacific Biologics Market
10.1. Asia-Pacific Biologics Market Overview
10.2. Asia-Pacific Biologics Historic Market, 2013-2017
10.3. Asia-Pacific Biologics Forecast Market, 2017-2021
10.4. Asia-Pacific Biologics Market, 2017, By Segment
10.5. Asia-Pacific Biologics Market: Country Analysis
10.6. China Biologics Market Overview
10.6.1. China Biologics Historic Market, 2013-2017
10.6.2. China Biologics Forecast Market, 2017-2021
10.6.3. China Biologics Market, 2017, By Segment
10.7. India Biologics Market Overview
10.7.1. India Biologics Historic Market, 2013-2017
10.7.2. India Biologics Forecast Market, 2017-2021
10.7.3. India Biologics Market, 2017, By Segment
10.8. Japan Biologics Market Overview
10.8.1. Japan Biologics Historic Market, 2013-2017
10.8.2. Japan Biologics Forecast Market, 2017-2021
10.8.3. Japan Biologics Market, 2017, By Segment
10.9. Australia Biologics Market Overview
10.9.1. Australia Biologics Historic Market, 2013-2017
10.9.2. Australia Biologics Forecast Market, 2017-2021
10.9.3. Australia Biologics Market, 2017, By Segment
11. Western Europe Biologics Market
11.1. Western Europe Biologics Market Overview
11.2. Western Europe Biologics Historic Market, 2013-2017
11.3. Western Europe Biologics Forecast Market, 2017-2021
11.4. Western Europe Biologics Market, 2017, By Segment
11.5. Western Europe Biologics Market: Country Analysis
11.6. UK Biologics Market Overview
11.6.1. UK Biologics Historic Market, 2013-2017
11.6.2. UK Biologics Forecast Market, 2017-2021
11.6.3. UK Biologics Market, 2017, By Segment
11.7. Germany Biologics Market Overview
11.7.1. Germany Biologics Historic Market, 2013-2017
11.7.2. Germany Biologics Forecast Market, 2017-2021
11.7.3. Germany Biologics Market, 2017, By Segment
11.8. France Biologics Market Overview
11.8.1. France Biologics Historic Market, 2013-2017
11.8.2. France Biologics Forecast Market, 2017-2021
11.8.3. France Biologics Market, 2017, By Segment
11.9. Italy Biologics Market Overview
11.9.1. Italy Biologics Historic Market, 2013-2017
11.9.2. Italy Biologics Forecast Market, 2017-2021
11.9.3. Italy Biologics Market, 2017, By Segment
11.10. Spain Biologics Market Overview
11.10.1. Spain Biologics Historic Market, 2013-2017
11.10.2. Spain Biologics Forecast Market, 2017-2021
11.10.3. Spain Biologics Market, 2017, By Segment
12. Eastern Europe Biologics Market
12.1. Eastern Europe Biologics Market Overview
12.2. Eastern Europe Biologics Historic Market, 2013-2017
12.3. Eastern Europe Biologics Forecast Market, 2017-2021
12.4. Eastern Europe Biologics Market, 2017, By Segment
12.5. Eastern Europe Biologics Market: Country Analysis
12.6. Russia Biologics Market Overview
12.6.1. Russia Biologics Historic Market, 2013-2017
12.6.2. Russia Biologics Forecast Market, 2017-2021
12.6.3. Russia Biologics Market, 2017, By Segment
13. North America Biologics Market
13.1. North America Biologics Market Overview
13.2. North America Biologics Historic Market, 2013-2017
13.3. North America Biologics Forecast Market, 2017-2021
13.4. North America Biologics Market, 2017, By Segment
13.5. North America Biologics Market: Country Analysis
13.6. USA Biologics Market Overview
13.6.1. USA Biologics Historic Market, 2013-2017
13.6.2. USA Biologics Forecast Market, 2017-2021
13.6.3. USA Biologics Market, 2017, By Segment
14. South America Biologics Market
14.1. South America Biologics Market Overview
14.2. South America Biologics Historic Market, 2013-2017
14.3. South America Biologics Forecast Market, 2017-2021
14.4. South America Biologics Market, 2017, By Segment
14.5. South America Biologics Market: Country Analysis
14.6. Brazil Biologics Market Overview
14.6.1. Brazil Biologics Historic Market, 2013-2017
14.6.2. Brazil Biologics Forecast Market, 2017-2021
14.6.3. Brazil Biologics Market, 2017, By Segment
15. Middle East Biologics Market
15.1. Middle East Biologics Market Overview
15.2. Middle East Biologics Historic Market, 2013-2017
15.3. Middle East Biologics Forecast Market, 2017-2021
15.4. Middle East Biologics Market, 2017, By Segment
16. Africa Biologics Market
16.1. Africa Biologics Market Overview
16.2. Africa Biologics Historic Market, 2013-2017
16.3. Africa Biologics Forecast Market, 2017-2021
16.4. Africa Biologics Market, 2017, By Segment
17. Competitive Landscape
17.1. Amgen
17.2. AbbVie Inc.
17.3. Johnson & Johnson
17.4. Bristol-Myers Squibb Company
17.5. Pfizer Inc.
17.6. Eli Lilly And Company
17.7. F. Hoffmann-La Roche Ltd.
17.8. Merck & Co.
17.9. GlaxosmithKline Plc.
17.10. Sanofi S.A.
18. Biologics Market Key Mergers And Acquisitions
19. Appendix
19.1. Abbreviations
19.2. Currencies
19.3. Research Inquiries
19.4. The Business Research Company
19.5. Copyright and Disclaimer

Executive Summary
The biologics industry comprises companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, vaccines, and monoclonal antibodies. These products are isolated from natural sources such as human, animal, and microorganisms by biotechnological methods and other cutting-edge technologies.

North America was the largest geographic region in the Global Biologics market in 2017, accounting for $87.3 billion of the market. Western Europe was the second largest geographic market, accounting for $51 billion of the market. Asia Pacific was the third largest geographic market, accounting for $35.6 billion of the market. Eastern Europe accounted for $14 billion, while Middle East accounted for $13.1 billion of the Global Biologics market.

Demand For Biologics In The Treatment Of Complex Diseases
Biologics are being widely used to provide effective treatment for many complex diseases such as rheumatoid arthritis, psoriasis, Crohn’s disease that have limited treatment options. There has been a significant advance in the treatment of rheumatoid arthritis patients who do not respond to traditional disease-modifying anti-rheumatic drugs. The key biologics used for the treatment of rheumatoid arthritis include Abatacept (Orencia), Adalimumab (Humira), Anakinra (Kineret), Infliximab (Remicade), and Rituximab (Rituxan). Key biologics used to treat psoriasis include Adalimumab (Humira), Etanercept (Enbrel), Infliximab (Remicade), Secukinumab ( Cosentyx). Cimzia (certolizumab pegol), Humira (adalimumab), and Remicade (infliximab), Tysabri (natalizumab) are biologics that are used to treat Crohn’s disease.
Get Customized Report
Please fill in your details. Our team will get back to you